Post hoc subgroup analysis of the HEART2D trial demonstrates lower cardiovascular risk in older patients targeting postprandial versus fasting/premeal glycemia
about
ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD - SummaryCurrent perspectives on cardiovascular outcome trials in diabetesTreatment intensification in patients with inadequate glycemic control on basal insulin: rationale and clinical evidence for the use of short-acting and other glucagon-like peptide-1 receptor agonistsLower rate of cardiovascular complications in patients on bolus insulin analogues: a retrospective population-based cohort studyDo data in the literature indicate that glycaemic variability is a clinical problem? Glycaemic variability and vascular complications of diabetes.Metrics Beyond Hemoglobin A1C in Diabetes Management: Time in Range, Hypoglycemia, and Other Parameters.Impact of postprandial hyperglycemia at clinic visits on the incidence of cardiovascular events and all-cause mortality in patients with type 2 diabetes.Glycemic variability and oxidative stress: a link between diabetes and cardiovascular disease?Utility of different glycemic control metrics for optimizing management of diabetesImportance of Beta Cell Function for the Treatment of Type 2 DiabetesAssociation of 1,5-Anhydroglucitol With Cardiovascular Disease and Mortality.Major adverse cardiovascular events with basal insulin peglispro versus comparator insulins in patients with type 1 or type 2 diabetes: a meta-analysis.Hemoglobin A1c variability as an independent correlate of cardiovascular disease in patients with type 2 diabetes: a cross-sectional analysis of the renal insufficiency and cardiovascular events (RIACE) Italian multicenter study.Intensification of insulin therapy for type 2 diabetic patients in primary care: basal-bolus regimen versus premix insulin analogs: when and for whom?Current insulin analogues in the treatment of diabetes: emphasis on type 2 diabetes.Evolution of insulin development: focus on key parameters.What are the preferred strategies for control of glycaemic variability in patients with type 2 diabetes mellitus?The role of glycemic index and glycemic load in cardiovascular disease and its risk factors: a review of the recent literature.Postprandial Dysmetabolism and Oxidative Stress in Type 2 Diabetes: Pathogenetic Mechanisms and Therapeutic Strategies.Dapagliflozin combination therapy in type 2 diabetes mellitus.A review of glucagon-like peptide-1 receptor agonists and their effects on lowering postprandial plasma glucose and cardiovascular outcomes in the treatment of type 2 diabetes mellitus.Outcome studies and safety as guide for decision making in treating patients with type 2 diabetes.Relations of Postload and Fasting Glucose With Incident Cardiovascular Disease and Mortality Late in Life: The Cardiovascular Health Study.Relationship between hemoglobin glycation index and extent of coronary heart disease in individuals with type 2 diabetes mellitus: a cross-sectional study.Postprandial glucose: marker or risk factor?Treatment with insulin analogs and prevalence of cardiovascular complications in patients with type 1 diabetes.Postprandial Blood Glucose Outweighs Fasting Blood Glucose and HbA1c in screening Coronary Heart Disease.Impact of improving postprandial glycemic control with intensifying insulin therapy in type 2 diabetes.
P2860
Q22241786-CAEC0821-B5AD-4F1A-95F8-589A78753B06Q28066006-7A7EFABA-3794-4C77-8901-3D337F16BB15Q28077026-B7E3CFB2-02D9-4E64-85AB-D1D08F8CD499Q28534935-C6C9085E-F0D4-44E4-9EB7-FD4550C3E748Q30666747-9E4B06F6-A2AF-413E-8673-41271DCA7CB5Q33727475-45C7870B-BF55-4236-A7E9-1ECB43EC5CE3Q33871377-11743145-3861-4FD4-BF63-1FAC40D6E511Q34486820-35A7AA9A-E1FE-414D-8517-E4DA1369AACDQ35049855-264EBF75-713B-4EC2-A960-0BC86C13D5D0Q35667116-41535F61-3401-4583-9439-5FCD9DD8C7AEQ36392849-5EDE7CBA-78A4-44F2-B32B-88403BB9ABF5Q36907339-8CAF897D-946D-4525-9EC0-B7F6B515586AQ37113138-7EB2512B-E4F0-44A4-A2B9-8ECD8C32C425Q37577153-054D0EAF-A4BB-414B-A88B-D81D991326B5Q37972941-8DB42F22-7942-483C-85B3-D7ACE17F5106Q38030454-9EB9F187-224C-4D07-A41C-D108B53A1A3CQ38137389-7DE72FB6-15C9-4FDD-A9BB-4FB3A349A7F8Q38165805-C677F8D5-4E87-4531-BDC7-4E4071A758E4Q38460480-61AA4A5C-307B-4419-8479-BC643F3A77F1Q38634051-48281F25-E215-4FB3-8567-4124DEA5779CQ38802810-E222C6CE-8904-4A71-AB70-FC036D9003BEQ38815498-AE9D8B5C-EE03-409C-8CDF-F5E86BAA3AFCQ40599277-49231E82-5E60-49B7-8C55-58CCDD5DF61CQ42270747-2219D5B8-B5AD-4869-8770-09347098D2D9Q42731432-C7BE3BF4-D56F-4DB6-98AC-5D29F47F3004Q47140717-44D92124-9414-48B2-BB3A-03F6755026FCQ47145958-6F3C33D9-D29D-45B6-9D6B-77AB76453862Q47443616-9723FD07-3113-4C72-ADE7-53650E410785
P2860
Post hoc subgroup analysis of the HEART2D trial demonstrates lower cardiovascular risk in older patients targeting postprandial versus fasting/premeal glycemia
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Post hoc subgroup analysis of ...... ersus fasting/premeal glycemia
@en
Post hoc subgroup analysis of ...... ersus fasting/premeal glycemia
@nl
type
label
Post hoc subgroup analysis of ...... ersus fasting/premeal glycemia
@en
Post hoc subgroup analysis of ...... ersus fasting/premeal glycemia
@nl
prefLabel
Post hoc subgroup analysis of ...... ersus fasting/premeal glycemia
@en
Post hoc subgroup analysis of ...... ersus fasting/premeal glycemia
@nl
P2093
P2860
P356
P1433
P1476
Post hoc subgroup analysis of ...... ersus fasting/premeal glycemia
@en
P2093
Cate A Jones
Chakib Battioui
Itamar Raz
Peter W Wilson
Scott J Jacober
Zvonko Milicevic
P2860
P304
P356
10.2337/DC10-2375
P407
P577
2011-05-18T00:00:00Z